What Is ACE-031?
ACE-031 is an experimental biologic that has been created in order to study the regulation of skeletal muscle growth and the signaling pathways associated with it. It is a recombinant fusion protein made up of the extracellular domain of activin receptor type IIB, or ActRIIB, joined to the Fc portion of human immunoglobulin G1. On this basis, ACE-031 belongs to the group of soluble receptor-Fc fusion proteins and not to the category of conventional small-molecule compounds or peptides.
The main molecular target is not a single protein but a number of ligands from the transforming growth factor beta superfamily, such as myostatin, activins, and other molecules that can bind to ActRIIB. ACE-031 has been investigated for its ability to alter signaling via the pathways associated with ActRIIB by functioning as a soluble ligand trap under controlled experimental conditions.
ACE-031 is found in the published scientific literature because these pathways play a close role in skeletal muscle biology, in the regulation of tissue growth, in body composition, and in cellular signaling. Research into the compound has been carried out in animal models, nonhuman primates, healthy volunteers, and in some clinical settings. Areas of investigation have included muscle fiber morphology, lean mass, muscle function, bone-related measurements, and the vascular effects resulting from broader ligand inhibition. Nevertheless, the existing body of evidence is still mainly preclinical, and the human studies available are small in size and of short duration.
Research Overview Table
Chemical and Molecular Characteristics
ACE-031 is a recombinant fusion protein having a modular molecular structure that fuses the extracellular ligand-binding domain of human activin receptor type IIB (ActRIIB) with the Fc region of human immunoglobulin G1 (IgG1). This approach results in a molecule that is considerably larger and more structurally complex than synthetic peptides or low-molecular-weight research compounds. Unlike short peptide sequences that usually interact with just one receptor or signaling pathway, ACE-031 acts as a soluble receptor molecule and is capable of binding a number of ligands from the transforming growth factor beta superfamily.
Since it is a glycoprotein biologic, its physicochemical properties are affected by various factors such as protein folding, the formation of disulfide bonds, glycosylation, and dimerization. These structural characteristics enhance molecular stability and therefore play a significant role when carrying out analytical characterization and handling in the laboratory. Given that recombinant fusion proteins have a higher level of structural complexity compared to chemically synthesized molecules, it is generally necessary to use a number of different analytical techniques rather than relying on a single assay for confirmation of identity and purity. Commonly employed methods include SDS-PAGE, Western blotting, size-exclusion chromatography and mass spectrometry, and these are used together with batch-specific records to ensure molecular integrity and consistency.
These features mean that ACE-031 is a unique research reagent for use in studies that require a biologic with a defined structure and one that can interact reproducibly with extracellular signaling ligands under controlled laboratory conditions.
Certificates:
Mechanism of Action Under Investigation
ACE-031 has been studied as a soluble ligand trap capable of modulating signaling via the activin receptor type IIB (ActRIIB) pathway. Instead of acting as an enzyme or directly inhibiting an intracellular catalytic process, the recombinant fusion protein is made up of the extracellular domain of ActRIIB attached to the Fc region of human immunoglobulin G1. This arrangement allows ACE-031 to bind certain extracellular ligands before these ligands can interact with the membrane-bound ActRIIB receptors on the target cells.
The main ligands that have been studied in published research are myostatin (GDF-8), activin A, and a number of other members of the transforming growth factor beta superfamily. When normal physiological conditions exist, these ligands trigger ActRIIB-mediated signaling by phosphorylating SMAD2 and SMAD3 proteins, thereby bringing about the regulation of gene transcription related to tissue growth, cellular differentiation, and protein turnover. ACE-031 has been looked at for its ability to decrease ligand availability by binding up these ligands in the extracellular environment under controlled experimental conditions.
These molecular interactions have been studied by combining a number of biochemical, cellular, and physiological methods. To determine receptor affinity, ligand-binding assays have been carried out, and cultured-cell reporter assays as well as immunoblotting have been used to examine changes in SMAD2/3 phosphorylation and other related signaling events. Gene expression analyses, such as quantitative polymerase chain reaction and transcriptomic profiling, have been carried out in order to look at the modifications in the downstream molecular pathways. In animal models, the researchers have added to these methods histological examination of the muscle tissue, morphometric analysis of the muscle fibers, measurements of body composition, and functional evaluations in order to investigate the wider biological effects of altered ActRIIB signaling. Clinical studies have also included pharmacokinetic analyses together with biomarkers of body composition and imaging-based assessments of muscle volume.
Even though these studies have shown that ACE-031 binds to multiple ActRIIB ligands and affects the relevant signaling pathways, there are still some aspects that are not completely understood. The individual contribution of each ligand to the molecular responses observed has not been fully clarified, and the wide range of ligands that it binds makes interpretation difficult since multiple signaling networks could be affected at the same time. Moreover, the vascular adverse events that were reported during clinical development indicate that the inhibition of ligands other than myostatin, including those involved in vascular homeostasis, may be responsible for off-target biological effects. As a result, the actual relationship between ligand sequestration, the subsequent changes in signaling, and the tissue-specific responses is still an area that is being actively investigated.
Scientific Research Context
ACE-031 is known in the scientific literature as a biologic that has been used experimentally to study ActRIIB-associated signaling and the biological regulation of skeletal muscle and related tissues. Published research has examined the compound in a variety of laboratory situations, such as in cell-based experiments, in animal models, in studies on nonhuman primates, and in a small number of early-stage human clinical investigations. The research has been directed at explaining molecular pathways, tissue morphology, body composition, pharmacokinetics, and safety under controlled experimental conditions. Nevertheless, the evidence currently available is mainly based on in vitro systems and preclinical animal studies, with relatively little human data available for interpretation.
ACE-031 Biology and Biological Pathways
Primary Biological Function
The biological pathways that are being studied in research on ACE-031 revolve around the way the activin receptor type IIB (ActRIIB) signaling network regulates tissue growth. This receptor is a part of the TGF-Ξ² (transforming growth factor beta) superfamily, a group of signaling systems that control cellular growth, differentiation, tissue remodeling and developmental processes. Scientists are looking into these pathways since they have an effect on the balance between protein synthesis and protein breakdown and also play a role in maintaining skeletal muscle, connective tissue, and bone. As a number of ligands are able to activate ActRIIB, the pathway functions as a complex signaling hub rather than involving a single molecular target, which is why it remains an area of ongoing interest in experimental biology.
Relevant Metabolic or Signaling Pathways
Most studies focus on the signaling events linked to the SMAD2 and SMAD3 transcriptional pathway after ActRIIB has been activated. Besides the canonical SMAD signaling, scientists have investigated interactions with wider molecular networks that play a role in the regulation of cellular growth, such as those connected with AKT, mTOR, MAPK, and protein homeostasis. It is believed that the interaction between these signaling systems affects gene expression, the remodeling of the extracellular matrix, and cellular adaptation in different physiological conditions. Since ActRIIB binds to many members of the TGF-Ξ² superfamily, researchers also look at how changes in one signaling pathway may impact other related biological networks, such as those concerned with vascular biology and connective tissue physiology.
Tissue-Specific Biology
A great deal of the research that has been published has been directed towards skeletal muscle since ActRIIB ligands are known to play an important role in the development, maintenance, and remodeling of muscle. In experimental studies, muscle fiber morphology, the cross-sectional area of the fibers, and changes in tissue composition are usually investigated under controlled laboratory conditions. Bone has also been looked at because some of the ActRIIB ligands are involved in skeletal development and in bone remodeling. Moreover, vascular tissues have come under examination as early clinical studies had indicated biological effects that go beyond skeletal muscle. These findings have therefore led to further research into the specific functions of the ligands in a number of different organ systems and not just within muscle.
Experimental Biomarkers
To characterize the biological responses linked with ActRIIB signaling, researchers make use of a combination of molecular, biochemical, and structural biomarkers. Typical laboratory endpoints include the levels of phosphorylated SMAD2 and SMAD3 proteins, the expression of genes that are involved in muscle growth and protein turnover, the concentrations of the relevant ligands in the circulation, and indicators of extracellular matrix remodeling. Histological measures such as muscle fiber diameter, lean body mass, and tissue composition are often included together with the biochemical analyses. Pharmacokinetic measurements and the receptor-binding properties are also assessed in order to gain a better understanding of the fusion protein's biological behavior during the course of the experimental studies.
Experimental Models Used in Published Research
A variety of complementary models have been used in experimental studies of ACE-031 in order to look at different aspects of ActRIIB-associated biology. Each of these models focuses on a separate scientific question, ranging from molecular signaling in isolated cells to tissue-level responses in whole organisms and to the assessment of pharmacokinetic behavior in humans. Taken together, these methods lead to a more comprehensive understanding of the biological systems being studied and at the same time point out the limitations involved in transferring experimental results from laboratory models to clinical settings.
Cell Culture Models
Using cell-based systems, researchers are able to study ligand-receptor interactions and the subsequent signaling processes under carefully controlled conditions in the laboratory. Such studies generally measure molecular endpoints including receptor activation, intracellular signaling proteins, and alterations in gene expression. Even though these models offer valuable insights into mechanisms, they are unable to replicate the complexity of the interactions that take place between different tissues in living organisms.
Mouse Models
Mouse models are so widely used because they enable the study of whole-body physiology at the same time as environmental and genetic variables can be carefully controlled. Researchers usually carry out evaluations of tissue morphology, body composition, histological characteristics, and molecular biomarkers together with functional assessments. Although mice do provide valuable biological information, differences specific to the species in terms of physiology and ligand biology prevent direct extrapolation to humans.
Nonhuman Primate Models
Nonhuman primates are used in research when the researchers need a model whose anatomy, musculoskeletal physiology, and protein homology are more similar to those of humans. Such studies involve the use of imaging, measurements of body composition, tissue analysis, and physiological testing in order to look at the overall biological responses. Due to practical, ethical, and financial factors, the number of samples available is usually limited, which in turn reduces the statistical power and restricts the scope of the investigation.
Early-Phase Human Clinical Studies
The early clinical studies are mainly concerned with describing pharmacokinetics, pharmacodynamics, tolerability, and the responses of biomarkers under closely supervised conditions. The measurements taken can comprise circulating biomarkers, assessments of body composition, imaging-based evaluations, and standard clinical safety parameters. Such studies typically have a relatively small number of participants and a short period of follow-up, which is why they are not appropriate for determining long-term biological or clinical effects.
Histological and Tissue Analysis
The structural details that cannot be gained merely from imaging are provided by the microscopic examination of tissue samples. Researchers use established histological techniques to assess features including muscle fiber morphology, fiber cross-sectional area, cellular organization, and tissue architecture. Even though these methods give detailed anatomical information, the tissue processing only reflects a single point in time and is therefore unable to fully record dynamic biological processes.
Molecular and Biochemical Analysis
Molecular investigations are employed in order to characterize the signaling pathways and the changes in gene or protein expression linked with ActRIIB biology. The usual laboratory methods involve immunoblotting, quantitative polymerase chain reaction, immunoassays, and transcriptomic analyses. Although these techniques produce detailed biochemical data, they do require careful interpretation since molecular changes do not always correspond to the complex physiological responses seen at the organism level.
ACE-031 Published Scientific Research
Skeletal Muscle Biology
Published studies looking into skeletal muscle biology have focused on the effects of altering ActRIIB-associated signaling on muscle structure and the make-up of the tissue. The main evidence has been obtained from experiments with mice, followed by some research on common marmosets and a few early-phase clinical studies. The researchers measured a number of endpoints such as muscle weight, fiber cross-sectional area, fiber type distribution, lean body mass, and the ex vivo contractile properties by means of histology, immunohistochemistry, imaging, and morphometric analysis. Together, these models have increased our understanding of skeletal muscle biology in controlled laboratory settings. Yet, due to species differences, the small number of subjects involved, and the common use of healthy animals, direct application to human physiology is limited.
Pharmacokinetics and Body Composition
Clinical research has investigated the pharmacokinetic profile of ACE-031 together with laboratory assessments of body composition and pharmacodynamic activity. In the published studies, serum concentration analysis, magnetic resonance imaging, dual-energy X-ray absorptiometry, and circulating biomarkers have been used to describe the systemic exposure that occurs after administration. While these methods yield information regarding the biological behavior of the fusion protein under controlled clinical conditions, the evidence currently available comes from small early-phase studies with short follow-up periods and a limited number of participants.
Duchenne Muscular Dystrophy Research
Studies of Duchenne muscular dystrophy have been concerned with examining the biological effects of ACE-031 in a neuromuscular disease model. The researchers evaluated pharmacokinetics, body composition, bone-related measurements, pulmonary function, and some functional endpoints by using a randomized, placebo-controlled clinical approach. Even though this study has increased understanding of ACE-031 in the context of a disease state, the clinical program was stopped before it could be finished. As a result, the evidence is still very limited, and the data currently available do not allow for any definite conclusions about the longer-term biological responses.
Nonhuman Primate Research
Studies involving nonhuman primates were carried out in order to examine ACE-031 in a species whose musculoskeletal physiology is more similar to that of humans than is the case with standard rodent models. The researchers carried out longitudinal measurements of body composition together with a detailed histological evaluation and tests of muscle contractility performed outside of the body in order to describe the structural and physiological characteristics in a number of different tissues. Although these experiments do provide some useful translational information, they are still in the preclinical stage and are naturally limited by the small number of animals used and by the practical difficulties connected with primate research.
Vascular Biology and Off-Target Signaling
Other published work has looked at biological processes apart from skeletal muscle as a result of observations of vascular adverse events during clinical development. Later studies have examined how the wide ligand-binding profile of ACE-031 might affect the signaling pathways concerned with vascular homeostasis and the biology of connective tissue. A great deal of this evidence comes from the interpretation of mechanisms and from related experimental research rather than from specific studies on ACE-031, so some of the basic biology is still not fully understood.
Analytical Characterization
Recent publications have used analytical laboratory methods rather than biological models to determine the molecular composition of materials that are marketed as ACE-031. Techniques such as SDS-PAGE, Western blotting, and mass spectrometry have been employed in order to compare the products available on the market with the recombinant fusion protein as described in the initial development program. The studies highlight the need for analytical verification when interpreting published results and show that materials produced independently might not always correspond to the molecule that was assessed in peer-reviewed research.
Limitations of Current Research
Evidence Is Predominantly Preclinical
The majority of the research that has been published on ACE-031 has been carried out using cell-based systems, animal models, or nonhuman primates. Such experimental models offer valuable insight into biological mechanisms and tissue reactions under controlled conditions. It cannot be assumed, though, that the results obtained from preclinical research will predict the biological effects or outcomes in humans.
Human Clinical Evidence
The only human evidence comes from a small number of early-phase clinical studies which included only a relatively small number of participants. These studies were mainly aimed at assessing pharmacokinetics, pharmacodynamics, and safety rather than at determining long-term biological or clinical outcomes. As a result, the human data currently available offer only a limited basis for scientific interpretation.
Species Differences
Animal models are still necessary for the study of complex biological systems, but there are important physiological differences between species. Variations in receptor biology, the way ligands interact, metabolism, and tissue responses can affect the results of experiments. Since these differences exist, any observations made in rodents or nonhuman primates should be carefully interpreted when it comes to human biology.
Study Design Limitations
Many of the studies that have been published have used small sample sizes, have had relatively short periods of follow-up, or have focused on rather narrowly defined groups of experimental subjects. Moreover, one clinical development program was stopped before it was finished, which decreased the amount of data available. Taken together, these factors reduce the statistical power and limit the conclusions that can be reached from the present body of literature.
Independent Replication
While several peer-reviewed publications refer to ACE-031, only a small number of independent research groups have carried out direct investigations of the compound. A great deal of the early work was carried out during the drug's pharmaceutical development. Further studies by independent groups would increase confidence in the reproducibility of the observations reported in different laboratories and experimental conditions.
Long-Term Evidence
There is still a lack of long-term experimental evidence. The majority of the studies that have been published have looked at relatively short treatment periods or have involved a single dose, and as a result, the questions about prolonged biological effects remain unanswered. Further research would have to be carried out in order to better understand the sustained molecular, physiological, and safety-related observations obtained under extended experimental conditions.
Analytical Documentation
Analytical verification plays a vital role in laboratory research since it allows one to confirm that a material matches its intended molecular identity prior to starting any experimental work. High-performance liquid chromatography (HPLC) can be used to check the purity of many research compounds, and liquid chromatography-mass spectrometry (LC-MS) gives data on molecular mass and composition; for structurally complex biologics, such as recombinant fusion proteins like ACE-031, nuclear magnetic resonance (NMR) is generally less useful than it is for small molecules, and protein-specific analytical methods are usually preferred.
The only analytical documentation available for ACE-031 is a Certificate of Analysis (COA), this document providing a summary of the main quality control information obtained during manufacturing or at the time of batch release, such as the product's identity and the results of the relevant analytical tests.
Analytical documentation is meant for the purpose of confirming the identity and quality of a product when it is being used in a laboratory environment, and it fails to show or predict the biological activity, efficacy, or performance of the material in experimental systems.
Storage and Laboratory Handling
ACE-031 should be handled only by qualified laboratory staff following approved laboratory techniques. Store material as per the product specification and the batch documentation accompanying the material to maintain the sample integrity. Always keep containers well sealed while not in use. Use clean equipment to limit the chance of contamination or degradation of the sample. ACE-031 is supplied exclusively for laboratory research and is not intended for human or veterinary use.
Frequently asked questions
Why choose us?
Direct SARMs is an established supplier of research peptides. We are committed to product quality, reliable service, and helpful customer support.
Our European-made products undergo rigorous purity testing, with clear product information provided for each research material. We also aim to provide dependable shipping and a smooth ordering experience.
Our support team is available to assist with orders, shipping, payments, and general questions. At Direct SARMs, we aim to make the research supply process simple, clear, and reliable.